Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima - Peru.
COVID-19
Cats
Neutralizing antibodies
One health
SARS-CoV-2
Serology
Journal
One health (Amsterdam, Netherlands)
ISSN: 2352-7714
Titre abrégé: One Health
Pays: Netherlands
ID NLM: 101660501
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
26
05
2021
revised:
23
08
2021
accepted:
25
08
2021
pubmed:
1
9
2021
medline:
1
9
2021
entrez:
31
8
2021
Statut:
ppublish
Résumé
SARS-CoV-2 can infect a variety of wild and domestic animals worldwide. Of these, domestic cats are highly susceptible species and potential viral reservoirs. As such, it is important to investigate disease exposure in domestic cats in areas with active community transmission and high disease prevalence. In this report we demonstrate the presence of serum neutralizing antibodies against the receptor binding-domain (RBD) of the SARS-CoV-2 in cats whose owners had been infected with SARS-CoV-2 in Lima, Peru, using a commercial competitive ELISA SARS-CoV-2 Surrogate Virus Neutralization Test. Out of 41 samples, 17.1% (7/41) and 31.7% (13/41) were positive, using the cut-off inhibition value of 30% and 20%, respectively. Not all cats living in a single house had detectable neutralizing antibodies showing heterogenous exposure and immunity among cohabiting animals. This is the first report of SARS-COV-2 exposure of domestic cats in Lima, Peru. Further studies are required to ascertain the prevalence of SARS-COV-2 exposure among domestic cats.
Identifiants
pubmed: 34462726
doi: 10.1016/j.onehlt.2021.100318
pii: S2352-7714(21)00108-7
pmc: PMC8388143
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100318Subventions
Organisme : FIC NIH HHS
ID : D43 TW007393
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2021 The Authors. Published by Elsevier B.V.
Références
Viruses. 2021 May 19;13(5):
pubmed: 34069453
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Transbound Emerg Dis. 2021 Jun 28;:
pubmed: 34180590
Vaccines (Basel). 2020 Dec 17;8(4):
pubmed: 33348613
N Engl J Med. 2020 Aug 6;383(6):592-594
pubmed: 32402157
Transbound Emerg Dis. 2021 May;68(3):1075-1079
pubmed: 32946664
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33139421
Science. 2020 May 29;368(6494):1016-1020
pubmed: 32269068
PLoS One. 2021 Mar 25;16(3):e0248578
pubmed: 33765012
One Health. 2021 Jun;11:100192
pubmed: 33169106
J Microbiol Immunol Infect. 2021 Apr;54(2):175-181
pubmed: 32624360
Nature. 2020 Oct;586(7831):776-778
pubmed: 32408337
J Med Virol. 2021 Mar;93(3):1351-1360
pubmed: 33090532
Vet Q. 2021 Dec;41(1):181-201
pubmed: 33892621
Microbiol Resour Announc. 2020 May 28;9(22):
pubmed: 32467283
One Health. 2021 Dec;13:100313
pubmed: 34458548
Nat Commun. 2020 Dec 4;11(1):6231
pubmed: 33277505
Emerg Microbes Infect. 2020 Dec;9(1):2013-2019
pubmed: 32867625
Signal Transduct Target Ther. 2020 Sep 2;5(1):180
pubmed: 32879307
Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26382-26388
pubmed: 32994343
Front Vet Sci. 2020 Dec 11;7:596391
pubmed: 33363234